argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-09-21 07:39 |
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Cana…
|
English | 121.4 KB | ||
| 2023-09-15 08:38 |
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Genera…
|
English | 50.1 KB | ||
| 2023-08-30 07:44 |
argenx to Present at Upcoming Investor Conferences
|
English | 115.8 KB | ||
| 2023-07-27 07:53 |
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Bus…
|
English | 140.0 KB | ||
| 2023-07-25 07:48 |
argenx announces closing of global offering
|
English | 44.6 KB | ||
| 2023-07-20 07:49 |
argenx to Report Half Year 2023 Financial Results and Second Quarter Business U…
|
English | 21.3 KB | ||
| 2023-07-20 07:48 |
argenx announces full exercise of underwriters’ option to purchase additional A…
|
English | 59.4 KB | ||
| 2023-07-19 08:36 |
argenx raises $1.1 billion in gross proceeds in a global offering
|
English | 66.2 KB | ||
| 2023-07-18 07:50 |
argenx announces launch of proposed global offering
|
English | 63.8 KB | ||
| 2023-07-17 07:31 |
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Pa…
|
English | 137.9 KB | ||
| 2023-06-30 16:16 |
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) …
|
English | 98.1 KB | ||
| 2023-06-21 12:27 |
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo …
|
English | 1.1 MB | ||
| 2023-06-20 08:15 |
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multif…
|
English | 48.5 KB | ||
| 2023-05-31 08:20 |
argenx to Present at Upcoming Investor Conferences
|
English | 21.6 KB | ||
| 2023-05-04 07:56 |
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
|
English | 124.6 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
